Past performance does not predict future results. Informational only, not investment advice.
Platford Giles Richard (President, IBU at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 55,617 shares of TAK at an average $20.90, roughly $1,162,395, in a Form 4 filed 2026-11-05.
Bitetti Teresa Marie (President, OBU at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 46,609 shares of TAK at an average $20.89, roughly $973,662, in a Form 4 filed 2026-11-04.
Duprey Lauren Rusckowski (Chief Transformation Officer at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 34,535 shares of TAK at an average $18.54, roughly $640,279, in a Form 4 filed 2026-09-15.
Pacheco Rhonda Janice (President, U.S. Business Unit at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 16,901 shares of TAK at an average $17.10, roughly $289,007, in a Form 4 filed 2026-08-12.
Duprey Lauren Rusckowski (Chief Transformation Officer at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 47,586 shares of TAK at an average $17.10, roughly $813,721, in a Form 4 filed 2026-08-12.
Plump Andrew Stewart (President, R&D at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 165,393 shares of TAK at an average $17.10, roughly $2,828,220, in a Form 4 filed 2026-08-12.
Pignagnoli Agosti Marcello (Head, Strat. & Port. Dev at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 22,957 shares of TAK at an average $17.10, roughly $392,565, in a Form 4 filed 2026-08-12.
Bitetti Teresa Marie (President, OBU at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 50,012 shares of TAK at an average $17.10, roughly $855,205, in a Form 4 filed 2026-08-12.
Ricci Gabriele (Chief Data & Tech. Officer at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 25,088 shares of TAK at an average $17.10, roughly $429,005, in a Form 4 filed 2026-08-12.
Kim Julie So-Young (President and CEO at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 89,090 shares of TAK at an average $17.10, roughly $1,523,439, in a Form 4 filed 2026-08-12.
Platford Giles Richard (President, IBU at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 31,083 shares of TAK at an average $17.10, roughly $531,519, in a Form 4 filed 2026-08-12.
Furney Natalie Anne Marie (Global General Counsel at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 30,868 shares of TAK at an average $17.10, roughly $527,843, in a Form 4 filed 2026-08-12.
Shannon Elaine Mary (Pres., Global Supply & Quality at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 20,363 shares of TAK at an average $17.55, roughly $357,371, in a Form 4 filed 2026-08-12.
Greenway Nicola Deidre Petal (Chief Human Resources Officer at TAKEDA PHARMACEUTICAL CO LTD) reported an open-market sale of 34,603 shares of TAK at an average $17.51, roughly $605,778, in a Form 4 filed 2026-08-12.
End of results.